Apotex回忆了由于结晶化而产生的具体的ibuprofen胶囊,这些胶囊对健康构成低风险。 Apotex recalls specific ibuprofen capsules due to crystallization, posing low health risk.

某些Apotex Inc.的外力Ibuprofen液体Gel Capsules,400毫克(具体为1570621毫克和1570623毫克)正在加拿大被召回,原因是在Gelatin 壳内有ibuprofen结晶,造成阴云外表。 Certain lots of Apotex Inc.'s Extra Strength Ibuprofen Liquid Gel Capsules, 400 mg—specifically 1570621 and 1570623—are being recalled in Canada due to ibuprofen crystallizing inside the gelatin shell, causing a cloudy appearance. 加拿大卫生部于2025年11月24日发布了第2类召回通知,指出可能暂时对健康产生影响,但严重损害的风险较低。 Health Canada issued a Type 2 recall on November 24, 2025, indicating possible temporary health effects but low risk of serious harm. 敦促消费者检查他们的药品,与Apotex联系了解详情,并向加拿大卫生部报告关注事项。 Consumers are urged to check their medication, contact Apotex for details, and report concerns to Health Canada. 那些遇到健康问题的人应咨询保健提供者。 Those experiencing health issues should consult a healthcare provider. 未提供受影响产品的照片。 No photo of the affected product was provided. 更多信息可通过加拿大卫生部和加拿大食品检查署获取。 More information is available via Health Canada and the Canadian Food Inspection Agency.